Amyotrophic Lateral Sclerosis Clinical Trial
Official title:
An Expanded Access Protocol of Intravenous Trehalose Injection 90.5 mg/mL Treatment of Patients With Amyotrophic Lateral Sclerosis
NCT number | NCT05597436 |
Other study ID # | SLS-005-EAP |
Secondary ID | |
Status | No longer available |
Phase | |
First received | |
Last updated |
Verified date | April 2024 |
Source | Seelos Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Expanded Access |
This expanded access protocol is to provide access to the investigational product, SLS-005, to participants with ALS who are not eligible to participate in clinical trials.
Status | No longer available |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Sporadic or familial ALS. 2. Age 18 years or older. 3. Cohort 1: Patients who do not qualify for any reasonably accessible ongoing clinical trial. 4. Cohort 2: Patients who have completed the open label extension (OLE) period of Regimen E of the HEALEY ALS Platform Trial and are not eligible for enrollment in another treatment regimen of the platform study. 5. Capable of providing informed consent and complying with study procedures, in the Site Investigator's (SI's) opinion. 6. Participants have established care with a physician at the specialized ALS center involved in the study and will maintain this clinical care throughout the duration of the EAP. 7. Participants must have a life expectancy of at least 6 months in SI's opinion. Exclusion Criteria: 1. Current diagnosis or healthcare professional-recommended treatment (medication, exercise or diet) of diabetes mellitus. 2. Screening glucose >=140 mg/dl. 3. Known hypersensitivity to trehalose. 4. Current use of oral trehalose. 5. Inability for participant to return to site for weekly drug administration, until approved for home infusions. 6. Screening body weight >144 kilograms. 7. Participant with a history of any clinically significant or unstable medical condition or lab abnormality based on the SI's judgment that may interfere with assessment of the study objectives, with safety or full participation. 8. Females who are pregnant or nursing or who plan to get pregnant during the course of the EAP. 9. Females of child-bearing potential, or males, who are unwilling or unable to use highly effective methods of birth control. 10. Use of investigational treatments for ALS (as part of participation in a clinical trial or another EAP) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Screening Visit. 11. Permanent assisted ventilation (PAV), defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days. 12. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. 13. Presence of unstable psychiatric disease, cognitive impairment, dementia, or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion. 14. Patients who chose to take experimental medications and/or supplements, and that is the only reason they are not eligible for trials, won't be eligible for the EAP. |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado | Aurora | Colorado |
United States | University of Maryland School of Medicine | Baltimore | Maryland |
United States | Indiana University | Bloomington | Indiana |
United States | Saint Alphonsus Regional Medical Center | Boise | Idaho |
United States | Sean M. Healey & AMG Center for ALS Neurological Clinical Research Institute, Massachusetts General Hospital | Boston | Massachusetts |
United States | Texas Neurology, P.A.-Neal Site:769 | Dallas | Texas |
United States | Holy Cross Hospital - Phil Smith Neuroscience Institute | Fort Lauderdale | Florida |
United States | Nova Southeastern University | Fort Lauderdale | Florida |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | Hospital for Special Care | New Britain | Connecticut |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | Barrow Neurological Institute | Phoenix | Arizona |
United States | Virginia Commonwealth University Clinical Research Unit | Richmond | Virginia |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | University of California, San Francisco | San Francisco | California |
United States | SUNY Upstate Medical University | Syracuse | New York |
Lead Sponsor | Collaborator |
---|---|
Seelos Therapeutics, Inc. | Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |